Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
Metastasis From Malignant Tumor of Prostate (Disorder)
About this trial
This is an interventional diagnostic trial for Metastasis From Malignant Tumor of Prostate (Disorder) focused on measuring PSMA, Prostate Cancer, PET, SOLAR, Cu-64 PSMA
Eligibility Criteria
Inclusion Criteria: Patients with histologically proven prostate adenocarcinoma. Prior radical prostatectomy or radiation therapy with curative intent. Recurrence of disease defined as: Prior Radical Prostatectomy: PSA > 0.2 ng/mL, or Prior Radiation Therapy: 2 ng/mL rise in PSA over post-treatment nadir Patients with at least one extraprostatic site of disease suspected based on prior imaging or diagnosed by biopsy. Age greater than or equal to 18 years. Able to understand and provide signed written informed consent. Exclusion Criteria: Androgen deprivation therapy (ADT) or other therapies targeting the androgen pathway, unless subject has a rising PSA level. Body weight greater than 350 lb (158 kg). Investigational therapy within the past 30 days. Creatinine clearance (ClCr) less than 30 mL/min. Participants who are capable of fathering a child and who are unwilling to take precautions to prevent pregnancy.
Sites / Locations
- Yale University
- Edward Hines, Jr. VA Hospital
- Johns Hopkins University
- Saint Louis University
- John J. Cochran Veterans Hospital
- Washington University
- Nebraska Cancer Specialists
- XCancer Omaha/Urology Cancer Center
- MD Anderson
Arms of the Study
Arm 1
Experimental
Diagnostic Imaging with 64Cu-PSMA-I&T
64Cu-PSMA I&T